170 related articles for article (PubMed ID: 17640442)
1. Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder.
Tauscher-Wisniewski S; Disch D; Plewes J; Ball S; Beasley CM
Psychol Med; 2007 Nov; 37(11):1585-93. PubMed ID: 17640442
[TBL] [Abstract][Full Text] [Related]
2. Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.
Beasley CM; Ball SG; Nilsson ME; Polzer J; Tauscher-Wisniewski S; Plewes J; Acharya N
J Clin Psychopharmacol; 2007 Dec; 27(6):682-6. PubMed ID: 18004137
[TBL] [Abstract][Full Text] [Related]
3. Suicidality in pediatric patients treated with antidepressant drugs.
Hammad TA; Laughren T; Racoosin J
Arch Gen Psychiatry; 2006 Mar; 63(3):332-9. PubMed ID: 16520440
[TBL] [Abstract][Full Text] [Related]
4. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder.
Phillips KA; Kelly MM
Int Clin Psychopharmacol; 2009 Jan; 24(1):26-8. PubMed ID: 19060721
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between fluoxetine and suicidality in bulimia nervosa.
Wheadon DE; Rampey AH; Thompson VL; Potvin JH; Masica DN; Beasley CM
J Clin Psychiatry; 1992 Jul; 53(7):235-41. PubMed ID: 1639742
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.
Tollefson GD; Fawcett J; Winokur G; Beasley CM; Potvin JH; Faries DE; Rampey AH; Sayler ME
Ann Clin Psychiatry; 1993 Dec; 5(4):209-24. PubMed ID: 8312978
[TBL] [Abstract][Full Text] [Related]
7. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
8. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
Beasley CM; Dornseif BE; Bosomworth JC; Sayler ME; Rampey AH; Heiligenstein JH; Thompson VL; Murphy DJ; Masica DN
BMJ; 1991 Sep; 303(6804):685-92. PubMed ID: 1833012
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
[TBL] [Abstract][Full Text] [Related]
10. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.
Gibbons RD; Brown CH; Hur K; Davis J; Mann JJ
Arch Gen Psychiatry; 2012 Jun; 69(6):580-7. PubMed ID: 22309973
[TBL] [Abstract][Full Text] [Related]
11. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.
Bridge JA; Iyengar S; Salary CB; Barbe RP; Birmaher B; Pincus HA; Ren L; Brent DA
JAMA; 2007 Apr; 297(15):1683-96. PubMed ID: 17440145
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine: no association with suicidality in obsessive-compulsive disorder.
Beasley CM; Potvin JH; Masica DN; Wheadon DE; Dornseif BE; Genduso LA
J Affect Disord; 1992 Jan; 24(1):1-10. PubMed ID: 1545040
[TBL] [Abstract][Full Text] [Related]
13. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
Tollefson GD; Rampey AH; Beasley CM; Enas GG; Potvin JH
J Clin Psychopharmacol; 1994 Jun; 14(3):163-9. PubMed ID: 8027412
[TBL] [Abstract][Full Text] [Related]
14. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
Goldstein DJ; Rampey AH; Potvin JH; Masica DN; Beasley CM
J Clin Psychiatry; 1993 Aug; 54(8):309-16. PubMed ID: 8253699
[TBL] [Abstract][Full Text] [Related]
15. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
[TBL] [Abstract][Full Text] [Related]
16. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
[TBL] [Abstract][Full Text] [Related]
17. Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials.
Thase ME; Edwards J; Durgam S; Chen C; Chang CT; Mathews M; Gommoll CP
Int Clin Psychopharmacol; 2017 Sep; 32(5):281-288. PubMed ID: 28538024
[TBL] [Abstract][Full Text] [Related]
18. An increase in IL-6 levels at 6-month follow-up visit is associated with SSRI-emergent suicidality in high-risk children and adolescents treated with fluoxetine.
Amitai M; Taler M; Lebow M; Ben-Baruch R; Apter A; Fennig S; Weizman A; Chen A
Eur Neuropsychopharmacol; 2020 Nov; 40():61-69. PubMed ID: 32747326
[TBL] [Abstract][Full Text] [Related]
19. Newer generation antidepressants for depressive disorders in children and adolescents.
Hetrick SE; McKenzie JE; Cox GR; Simmons MB; Merry SN
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD004851. PubMed ID: 23152227
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy.
Kraus JE; Horrigan JP; Carpenter DJ; Fong R; Barrett PS; Davies JT
J Affect Disord; 2010 Jan; 120(1-3):40-7. PubMed ID: 19439363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
